Results 191 to 200 of about 3,585,369 (296)

Impact of Alcohol Consumption on Selected Cancer Incidence Trends among Adults in the United States, 2008 to 2019. [PDF]

Cancer Epidemiol Biomarkers Prev
Greene NK, Reyes-Guzman CM, Baker L, Meador E, Noone AM, Howlader N.   +5 more
europepmc   +1 more source

Câncer pediátrico: avaliação econômica de tecnologias que evitam efeitos colaterais ao tratamento

, 2018
Ricardo Ribeiro Alves Fernandes
openalex   +1 more source

Efeitos da Alimentação no Câncer de Mama em Mulheres

Sandy Maria Andrade Cardoso Fagundes Genovêz, Paula de Almeida Claudino   +1 more
openalex   +1 more source

Investigating the cell of origin and novel molecular targets in Merkel cell carcinoma: a historic misnomer

Molecular Oncology, EarlyView.
This study indicates that Merkel cell carcinoma (MCC) does not originate from Merkel cells, and identifies gene, protein & cellular expression of immune‐linked and neuroendocrine markers in primary and metastatic Merkel cell carcinoma (MCC) tumor samples, linked to Merkel cell polyomavirus (MCPyV) status, with enrichment of B‐cell and other immune cell
Richie Jeremian, Sriraam Sivachandran, Melissa Galati, Brandon Ramchatesingh, Hibo Rijal, Johnny Hanna, Elena Netchiporouk, May Chergui, Margaret Redpath, Samy Abou Setah, Ivan V. Litvinov   +10 more
wiley   +1 more source

Lifetime prevalence of cancer in Germany between 2010 and 2019: An analysis based on aggregated data. [PDF]

PLoS One
Baginski K, Voeltz D, Hornberg C, Kohring C, Hoyer A.   +4 more
europepmc   +1 more source

Perfil de ácidos graxos da dieta e do tecido adiposo mamário e o risco de desenvolvimento do câncer de mama: um estudo caso-controle

, 2008
Maria Carolina Santos Mendes
openalex   +1 more source

The influence of ROS1 fusion partners and resistance mechanisms in ROS1‐TKI‐treated non‐small cell lung cancer patients

Molecular Oncology, EarlyView.
This real‐world study of ROS1+ NSCLC highlights fusion diversity, treatment outcomes with crizotinib and lorlatinib, and in vitro experiments with resistance mechanisms. G2032R drives strong resistance to ROS1‐targeted TKIs, especially lorlatinib. Fusion partner location does not affect overall survival to crizotinib or lorlatinib. Findings support the
Fenneke Zwierenga, Christa Dijkhuizen, Patrick Korthuis, Wim Timens, Harry Groen, Jeroen Hiltermann, Anke van den Berg, Lyndsay Drayer, Anthonie van der Wekken   +8 more
wiley   +1 more source

GLP-1 receptor agonists and cancer: current clinical evidence and translational opportunities for preclinical research. [PDF]

J Clin Invest
Valencia-Rincón E, Rai R, Chandra V, Wellberg EA.   +3 more
europepmc   +1 more source

A reabilitação de mulheres com câncer de mama: uma análise descritiva do Núcleo de Ensino, Pesquisa e Assistência na Reabilitação de Mastectomizadas [PDF]

, 2007
Ana Maria de Almeida
openalex   +1 more source

YAP1::TFE3 mediates endothelial‐to‐mesenchymal plasticity in epithelioid hemangioendothelioma

Molecular Oncology, EarlyView.
The YAP1::TFE3 fusion protein drives endothelial‐to‐mesenchymal transition (EndMT) plasticity, resulting in the loss of endothelial characteristics and gain of mesenchymal‐like properties, including resistance to anoikis, increased migratory capacity, and loss of contact growth inhibition in endothelial cells.
Ant Murphy, Samuel Hartzler, Paula A. Vargas Carranza, Shyaman Jayasundara, Madison E. Yates, Nimod D. Janson, Bozhi Liu, Annaleigh Benton, Majid Kazemian, Jason A. Hanna   +9 more
wiley   +1 more source